OSSFF
Embla Medical hf.
Price Chart
Latest Quote
$4.15
+0.00 (+0.00%)
Current Price
| Previous Close | $4.15 |
| Open | $5.11 |
| Day High | $5.11 |
| Day Low | $5.11 |
| Volume | 40 |
Stock Information
| Shares Outstanding | 426.15M |
| Total Debt | $552.94M |
| Cash Equivalents | $93.66M |
| Revenue | $958.30M |
| Net Income | $85.63M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $1.77B |
| P/E Ratio | 20.75 |
| EPS (TTM) | $0.20 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.24B |
| Sales | $958.30M |
| Income | $85.63M |
| Book/sh | $2.10 |
| Cash/sh | $0.22 |
| Employees | 4K |
Financial Ratios
| Quick Ratio | 0.63 |
| Current Ratio | 1.21 |
| Debt/Eq | 61.13 |
| EPS Growth TTM | 18.90% |
Returns & Margins
| ROA | 4.76% |
| ROE | 10.10% |
| Gross Margin | 61.97% |
| Operating Margin | 9.74% |
| Profit Margin | 8.94% |
Ownership
| Insider Ownership | 12.41% |
| Institutional Ownership | 79.37% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 1.85 |
| P/B | 1.97 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $4.15 |
| SMA50 | $4.15 |
| SMA200 | $4.71 |
| RSI | nan |
| Shares Float | 157.31M |
| Volatility | 0.46 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | -3.49% |
| 6 Months | -22.07% |
| YTD | -22.07% |
| Year | +0.00% |
| 3 Years | -12.63% |
| 5 Years | -45.39% |
| 10 Years | -26.86% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $4.15 | 0 |
| 2026-06-17 | $4.15 | 0 |
| 2026-06-16 | $4.15 | 0 |
| 2026-06-15 | $4.15 | 0 |
| 2026-06-12 | $4.15 | 0 |
| 2026-06-11 | $4.15 | 0 |
| 2026-06-10 | $4.15 | 0 |
| 2026-06-09 | $4.15 | 0 |
| 2026-06-08 | $4.15 | 0 |
| 2026-06-05 | $4.15 | 0 |
| 2026-06-04 | $4.15 | 0 |
| 2026-06-03 | $4.15 | 0 |
| 2026-06-02 | $4.15 | 0 |
| 2026-06-01 | $4.15 | 0 |
| 2026-05-29 | $4.15 | 0 |
| 2026-05-28 | $4.15 | 0 |
| 2026-05-27 | $4.15 | 0 |
| 2026-05-26 | $4.15 | 0 |
| 2026-05-22 | $4.15 | 0 |
| 2026-05-21 | $4.15 | 0 |
| 2026-05-20 | $4.15 | 0 |
| 2026-05-19 | $4.15 | 0 |
About Embla Medical hf.
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides osteoarthritis solutions that are designed to reduce pain and improve mobility for people living with osteoarthritis; and injury solutions for people recovering from fractures, ligament injuries, or need post-operative treatment. This segment also offers Unloader One, a range knee braces that relieve pain from knee osteoarthritis; and Unloader Hip, which is designed to reduce pain by optimizing load dispersion for patients suffering from mild and moderate osteoarthritis of the hip. The Patient Care segment provides prosthetics for people with lower and upper limb loss or limb difference; and orthotics for neurological, gait, and musculoskeletal conditions. The company serves orthopedic and prosthetic clinics, hospitals, and surgery centers. It sells its products through its direct sales networks and distributors. The company was formerly known as Ãssur hf. and changed its name to Embla Medical hf. in April 2024. Embla Medical hf. was incorporated in 1971 and is headquartered in Reykjavik, Iceland. Embla Medical hf. is a subsidiary of William Demant Invest A/S.
đ° Latest News
Embla Medical hf (OSSUY) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amidst Margin ...
GuruFocus.com âĸ 2026-04-29T07:01:26ZAssessing Embla Medical hf (CPSE:EMBLA) Valuation After Stronger Full Year 2025 Earnings Results
Simply Wall St. âĸ 2026-02-09T05:04:28Z
Embla Medical hf (OSSUY) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ...
GuruFocus.com âĸ 2026-02-03T15:00:57ZAre Embla Medical Shares Attractive After Recent 2.3% Rise and Flat Year?
Simply Wall St. âĸ 2025-09-09T12:49:50Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $320,189,000 | $300,110,000 | $278,902,000 | $263,282,000 |
| Cost Of Revenue | $320,189,000 | $300,110,000 | $278,902,000 | $263,282,000 |
| Total Revenue | $854,889,000 | $785,683,000 | $718,650,000 | $718,669,000 |
| Operating Revenue | $854,889,000 | $785,683,000 | $718,650,000 | $718,669,000 |
| Expenses | ||||
| Interest Expense | $23,248,000 | $17,959,000 | $11,204,000 | $9,798,000 |
| Total Expenses | $742,136,000 | $698,223,000 | $651,511,000 | $623,045,000 |
| Other Non Operating Income Expenses | $399,000 | $1,927,000 | $-2,296,000 | $1,687,000 |
| Net Non Operating Interest Income Expense | $-21,496,000 | $-16,112,000 | $-11,641,000 | $-12,186,000 |
| Total Other Finance Cost | $214,000 | $1,601,000 | $1,216,000 | $2,556,000 |
| Interest Expense Non Operating | $23,248,000 | $17,959,000 | $11,204,000 | $9,798,000 |
| Operating Expense | $421,947,000 | $398,113,000 | $372,609,000 | $359,763,000 |
| Selling And Marketing Expense | $311,151,000 | $293,080,000 | $266,056,000 | $253,885,000 |
| General And Administrative Expense | $69,964,000 | $66,891,000 | $72,529,000 | $74,143,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $68,278,000 | $58,389,000 | $42,513,000 | $63,994,000 |
| Net Interest Income | $-21,496,000 | $-16,112,000 | $-11,641,000 | $-12,186,000 |
| Interest Income | $1,966,000 | $3,448,000 | $779,000 | $168,000 |
| Normalized Income | $68,278,000 | $58,389,000 | $42,513,000 | $63,994,000 |
| Net Income From Continuing And Discontinued Operation | $68,278,000 | $58,389,000 | $42,513,000 | $63,994,000 |
| Net Income Common Stockholders | $68,278,000 | $58,389,000 | $42,513,000 | $63,994,000 |
| Net Income | $68,278,000 | $58,389,000 | $42,513,000 | $63,994,000 |
| Net Income Including Noncontrolling Interests | $68,960,000 | $58,801,000 | $43,210,000 | $65,656,000 |
| Net Income Continuous Operations | $68,960,000 | $58,801,000 | $43,210,000 | $65,656,000 |
| Pretax Income | $90,563,000 | $76,007,000 | $56,172,000 | $86,640,000 |
| Interest Income Non Operating | $1,966,000 | $3,448,000 | $779,000 | $168,000 |
| Operating Income | $112,753,000 | $87,460,000 | $67,139,000 | $95,624,000 |
| Gross Profit | $534,700,000 | $485,573,000 | $439,748,000 | $455,387,000 |
| Total Operating Income As Reported | - | $89,387,000 | $64,844,000 | $97,311,000 |
| Per Share | ||||
| Diluted EPS | $0.16 | $0.14 | $0.10 | $0.15 |
| Basic EPS | $0.16 | $0.14 | $0.10 | $0.16 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $169,784,000 | $143,886,000 | $116,741,000 | $147,966,000 |
| Reconciled Depreciation | $55,973,000 | $49,920,000 | $49,365,000 | $51,528,000 |
| EBITDA (Bullshit earnings) | $169,784,000 | $143,886,000 | $116,741,000 | $147,966,000 |
| EBIT | $113,811,000 | $93,966,000 | $67,376,000 | $96,438,000 |
| Diluted Average Shares | $426,659,000 | $420,318,000 | $417,831,000 | $422,795,000 |
| Basic Average Shares | $426,644,000 | $420,297,000 | $417,758,000 | $422,161,000 |
| Diluted NI Availto Com Stockholders | $68,278,000 | $58,389,000 | $42,513,000 | $63,994,000 |
| Otherunder Preferred Stock Dividend | $0 | $0 | $0 | $0 |
| Minority Interests | $-682,000 | $-412,000 | $-697,000 | $-1,662,000 |
| Tax Provision | $21,603,000 | $17,206,000 | $12,962,000 | $20,984,000 |
| Research And Development | $40,832,000 | $38,142,000 | $34,024,000 | $31,735,000 |
| Selling General And Administration | $381,115,000 | $359,971,000 | $338,585,000 | $328,028,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-95,765,000 | $-54,813,000 | $-106,699,000 | $-81,403,000 |
| Total Assets | $1,538,965,000 | $1,385,682,000 | $1,325,361,000 | $1,246,915,000 |
| Total Non Current Assets | $1,142,010,000 | $1,009,706,000 | $976,514,000 | $928,684,000 |
| Non Current Deferred Taxes Assets | $46,365,000 | $41,888,000 | $37,320,000 | $27,044,000 |
| Financial Assets | $1,315,000 | $1,134,000 | $0 | - |
| Investmentin Financial Assets | $856,000 | $2,905,000 | $3,326,000 | $2,447,000 |
| Goodwill And Other Intangible Assets | $872,951,000 | $756,696,000 | $742,403,000 | $702,989,000 |
| Other Intangible Assets | $96,645,000 | $65,841,000 | $62,003,000 | $58,836,000 |
| Current Assets | $396,955,000 | $375,976,000 | $348,847,000 | $318,231,000 |
| Other Current Assets | $14,309,000 | $16,069,000 | $8,856,000 | $9,480,000 |
| Hedging Assets Current | $1,475,000 | $0 | - | - |
| Prepaid Assets | $22,630,000 | $17,660,000 | $14,497,000 | $14,045,000 |
| Inventory | $143,102,000 | $136,226,000 | $132,127,000 | $103,985,000 |
| Taxes Receivable | $7,361,000 | $5,524,000 | $4,364,000 | $2,756,000 |
| Accounts Receivable | $121,915,000 | $127,844,000 | $112,372,000 | $102,768,000 |
| Allowance For Doubtful Accounts Receivable | $-4,034,000 | $-5,076,000 | $-4,952,000 | $-5,273,000 |
| Gross Accounts Receivable | $125,949,000 | $132,920,000 | $117,324,000 | $108,041,000 |
| Cash Cash Equivalents And Short Term Investments | $86,163,000 | $72,653,000 | $76,631,000 | $85,197,000 |
| Cash And Cash Equivalents | $86,163,000 | $72,653,000 | $76,631,000 | $85,197,000 |
| Other Non Current Assets | - | $1,000 | $1,000 | - |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | - | $1,134,000 | $0 | - |
| Other Receivables | - | - | - | $1,135,000 |
| Debt | ||||
| Net Debt | $271,211,000 | $260,682,000 | $263,146,000 | $223,036,000 |
| Total Debt | $499,789,000 | $467,733,000 | $480,923,000 | $448,151,000 |
| Long Term Debt And Capital Lease Obligation | $447,033,000 | $424,407,000 | $394,085,000 | $380,864,000 |
| Long Term Debt | $328,754,000 | $311,802,000 | $277,709,000 | $262,190,000 |
| Current Debt And Capital Lease Obligation | $52,756,000 | $43,326,000 | $86,838,000 | $67,287,000 |
| Current Debt | $28,620,000 | $21,533,000 | $62,068,000 | $46,043,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $758,266,000 | $680,676,000 | $689,851,000 | $620,320,000 |
| Total Non Current Liabilities Net Minority Interest | $548,982,000 | $484,478,000 | $452,844,000 | $433,864,000 |
| Other Non Current Liabilities | $-1,000 | - | $-1,000 | $35,000 |
| Non Current Deferred Taxes Liabilities | $37,478,000 | $28,777,000 | $29,596,000 | $29,027,000 |
| Current Liabilities | $209,284,000 | $196,198,000 | $237,007,000 | $186,456,000 |
| Other Current Liabilities | $4,696,000 | $4,548,000 | $4,143,000 | $28,637,000 |
| Payables | $50,559,000 | $47,685,000 | $43,786,000 | $34,070,000 |
| Total Tax Payable | $23,284,000 | $16,936,000 | $15,133,000 | $7,350,000 |
| Accounts Payable | $27,275,000 | $30,749,000 | $28,653,000 | $26,720,000 |
| Derivative Product Liabilities | - | - | - | $7,700,000 |
| Equity | ||||
| Common Stock Equity | $777,186,000 | $701,883,000 | $635,704,000 | $621,586,000 |
| Total Equity Gross Minority Interest | $780,699,000 | $705,006,000 | $635,510,000 | $626,595,000 |
| Stockholders Equity | $777,186,000 | $701,883,000 | $635,704,000 | $621,586,000 |
| Other Equity Interest | $4,985,000 | $5,692,000 | $5,149,000 | $4,093,000 |
| Retained Earnings | $759,112,000 | $699,667,000 | $639,961,000 | $591,932,000 |
| Long Term Equity Investment | $20,364,000 | $20,532,000 | $13,751,000 | $13,647,000 |
| Other | ||||
| Treasury Shares Number | $701,647 | $701,647 | $2,711,302 | $739,862 |
| Ordinary Shares Number | $426,934,475 | $420,298,353 | $420,288,698 | $422,260,138 |
| Share Issued | $427,636,122 | $421,000,000 | $423,000,000 | $423,000,000 |
| Tangible Book Value | $-95,765,000 | $-54,813,000 | $-106,699,000 | $-81,403,000 |
| Invested Capital | $1,134,560,000 | $1,035,218,000 | $975,481,000 | $929,819,000 |
| Working Capital | $187,671,000 | $179,778,000 | $111,840,000 | $131,775,000 |
| Capital Lease Obligations | $142,415,000 | $134,398,000 | $141,146,000 | $139,918,000 |
| Total Capitalization | $1,105,940,000 | $1,013,685,000 | $913,413,000 | $883,776,000 |
| Minority Interest | $3,513,000 | $3,123,000 | $-194,000 | $5,009,000 |
| Additional Paid In Capital | $88,635,000 | $61,479,000 | $61,430,000 | $70,776,000 |
| Capital Stock | $4,829,000 | $4,781,000 | $4,781,000 | $4,795,000 |
| Common Stock | $4,829,000 | $4,781,000 | $4,781,000 | $4,795,000 |
| Non Current Deferred Revenue | $8,589,000 | $7,277,000 | $6,042,000 | $6,250,000 |
| Long Term Capital Lease Obligation | $118,279,000 | $112,605,000 | $116,376,000 | $118,674,000 |
| Long Term Provisions | $7,937,000 | $6,666,000 | $5,808,000 | $4,629,000 |
| Current Capital Lease Obligation | $24,136,000 | $21,793,000 | $24,770,000 | $21,244,000 |
| Current Provisions | $12,615,000 | $11,322,000 | $19,325,000 | $8,970,000 |
| Available For Sale Securities | $856,000 | $2,905,000 | $3,326,000 | $2,447,000 |
| Investmentsin Associatesat Cost | $20,364,000 | $20,532,000 | $13,751,000 | $13,647,000 |
| Goodwill | $776,306,000 | $690,855,000 | $680,400,000 | $644,153,000 |
| Net PPE | $199,625,000 | $186,059,000 | $179,320,000 | $182,080,000 |
| Accumulated Depreciation | $-88,445,000 | $-80,103,000 | $-77,779,000 | $-82,028,000 |
| Gross PPE | $288,070,000 | $266,162,000 | $257,099,000 | $264,108,000 |
| Other Properties | $4,012,000 | $2,706,000 | $2,484,000 | $2,739,000 |
| Machinery Furniture Equipment | $108,996,000 | $101,675,000 | $129,711,000 | $135,771,000 |
| Buildings And Improvements | $175,062,000 | $161,781,000 | $124,904,000 | $125,598,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $75,667,000 | $73,112,000 | $75,710,000 | $62,348,000 |
| Work In Process | $23,167,000 | $19,202,000 | $17,238,000 | $11,443,000 |
| Raw Materials | $44,268,000 | $43,913,000 | $39,179,000 | $30,194,000 |
| Other Inventories | - | $-1,000 | - | - |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $76,839,000 | $52,046,000 | $34,829,000 | $73,842,000 |
| Operating Activities | ||||
| Operating Cash Flow | $116,066,000 | $94,324,000 | $60,771,000 | $100,530,000 |
| Investing Activities | ||||
| Capital Expenditure | $-39,227,000 | $-42,278,000 | $-25,942,000 | $-26,688,000 |
| Investing Cash Flow | $-104,770,000 | $-57,147,000 | $-66,261,000 | $-59,447,000 |
| Net Other Investing Changes | $4,529,000 | $-2,966,000 | $1,465,000 | $1,181,000 |
| Financing Activities | ||||
| Financing Cash Flow | $5,761,000 | $-40,959,000 | $3,789,000 | $-51,073,000 |
| Net Other Financing Charges | $-9,647,000 | - | - | - |
| Repurchase Of Capital Stock | - | $0 | $-9,941,000 | $0 |
| Net Common Stock Issuance | - | $0 | $-9,941,000 | $0 |
| Other | ||||
| Repayment Of Debt | $0 | $-14,777,000 | $-65,797,000 | $-17,352,000 |
| Issuance Of Debt | $39,787,000 | $0 | $52,833,000 | $1,693,000 |
| End Cash Position | $86,163,000 | $72,653,000 | $76,631,000 | $85,197,000 |
| Other Cash Adjustment Outside Changein Cash | $-2,000 | - | $-1,000 | - |
| Beginning Cash Position | $72,653,000 | $76,631,000 | $85,197,000 | $102,363,000 |
| Effect Of Exchange Rate Changes | $-3,545,000 | $-196,000 | $-6,864,000 | $-7,176,000 |
| Changes In Cash | $17,057,000 | $-3,782,000 | $-1,701,000 | $-9,990,000 |
| Net Issuance Payments Of Debt | $39,787,000 | $-14,777,000 | $35,624,000 | $-29,697,000 |
| Net Long Term Debt Issuance | $39,787,000 | $-14,777,000 | $-12,964,000 | $-15,659,000 |
| Long Term Debt Payments | $0 | $-14,777,000 | $-65,797,000 | $-17,352,000 |
| Long Term Debt Issuance | $39,787,000 | $0 | $52,833,000 | $1,693,000 |
| Net Business Purchase And Sale | $-70,072,000 | $-11,903,000 | $-41,784,000 | $-33,940,000 |
| Purchase Of Business | $-70,072,000 | $-11,903,000 | $-41,784,000 | $-33,940,000 |
| Net PPE Purchase And Sale | $-39,227,000 | $-42,278,000 | $-16,547,000 | $-16,959,000 |
| Purchase Of PPE | $-39,227,000 | $-42,278,000 | $-16,547,000 | $-16,959,000 |
| Taxes Refund Paid | $-23,487,000 | $-20,349,000 | $-19,663,000 | $-16,298,000 |
| Interest Received Cfo | $3,238,000 | $4,733,000 | $1,581,000 | $880,000 |
| Interest Paid Cfo | $-24,082,000 | $-16,046,000 | $-13,112,000 | $-12,150,000 |
| Change In Working Capital | $-10,557,000 | $-11,107,000 | $-19,292,000 | $-21,611,000 |
| Change In Payable | $-2,279,000 | $14,896,000 | $10,942,000 | $7,758,000 |
| Change In Inventory | $-5,928,000 | $-2,268,000 | $-28,620,000 | $-15,783,000 |
| Change In Receivables | $-5,524,000 | $-16,370,000 | $-13,197,000 | $-13,184,000 |
| Depreciation And Amortization | $55,973,000 | $49,920,000 | $49,365,000 | $51,528,000 |
| Amortization Cash Flow | $12,165,000 | $9,794,000 | $10,466,000 | $11,667,000 |
| Depreciation | $43,808,000 | $40,126,000 | $38,899,000 | $39,861,000 |
| Net Income From Continuing Operations | $113,153,000 | $89,387,000 | $64,844,000 | $97,311,000 |
| Common Stock Payments | - | $0 | $-9,941,000 | $0 |
| Net Short Term Debt Issuance | - | $-1,575,000 | $48,588,000 | $-14,038,000 |
| Net Intangibles Purchase And Sale | - | $-13,045,000 | $-9,395,000 | $-9,729,000 |
| Purchase Of Intangibles | - | $-13,045,000 | $-9,395,000 | $-9,729,000 |
Fetched: 2026-02-02